Copyright: ©Author(s) 2026.
World J Meta-Anal. Sep 18, 2026; 14(3): 120937
Published online Sep 18, 2026. doi: 10.13105/wjma.120937
Published online Sep 18, 2026. doi: 10.13105/wjma.120937
Table 1 Causes of cholestatic pruritus
| Etiology | Examples | Typical features |
| Autoimmune | PBC, PSC | Chronic, nocturnal pruritus |
| Genetic | PFIC, ALGS | Severe, early onset |
| Hormonal | ICP | Third trimester |
| Drug-induced | Antibiotics, anabolic steroids | Temporal association |
| Obstructive | Malignancy, stones | Jaundice-predominant |
Table 2 Diagnostic tools and biomarkers
| Tool | Utility | Limitations |
| Serum bile acids | Reflect cholestasis | Poor correlation with symptom severity |
| Autotaxin | Emerging biomarker for cholestatic pruritus | Limited availability; not standardized |
| 5-D Itch Scale | Assesses multidimensional symptom severity | Subjective patient-reported measure |
| Imaging | Exclude biliary obstruction or malignancy | Does not quantify itch severity |
Table 3 Pharmacologic therapies for cholestatic pruritus
| Therapy | Mechanism | Evidence | Key adverse effects |
| Cholestyramine | Bile acid binding | Low | GI intolerance |
| Rifampin | PXR induction | Strong | Hepatotoxicity |
| Naltrexone | Opioid blockade | Moderate | Withdrawal symptoms |
| Sertraline | Central modulation | Low-moderate | Sexual dysfunction, weight gain |
| Fibrates | PPAR activator | Strong (recent) | Myalgia, transaminitis |
| IBAT inhibitors | BA circulation blockade | Strong (recent) | Diarrhea |
Table 4 Emerging and advanced therapies
| Therapy | Population studied | Clinical role |
| Odevixibat | PFIC, ALGS | Refractory pruritus |
| Maralixibat | ALGS | Pediatric cholestasis |
| Linerixibat | PBC | Adult cholestasis |
| Fibrates | PBC, PSC, SSC | Cholestatic pruritus |
| UVB phototherapy | Mixed etiologies | Adjunctive |
- Citation: Liu C, Elangovan A, Diaz DJ, Petrova L, Yekula A, Twohig P. Scratching the surface: A systematic review of modern approaches to diagnosing and treating cholestatic pruritus. World J Meta-Anal 2026; 14(3): 120937
- URL: https://www.wjgnet.com/2308-3840/full/v14/i3/120937.htm
- DOI: https://dx.doi.org/10.13105/wjma.120937